Business Wire

TX-PLANVIEW

1.5.2024 15:01:33 CEST | Business Wire | Press release

Share
Planview Accelerates Transformation Impact with Next Generation Connectivity, Visibility, and AI-Driven Insights

Planview, the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Development (DPD), today announced a series of platform innovations designed to accelerate the speed and impact of transformation by connecting project and product initiative data across the enterprise. These innovations enable bi-directional visibility and governance to create tighter alignment between strategies and teams, harness AI to enhance predictability and strategic decision-making, and deliver personalized user experiences to uplevel productivity.

“Organizations today are struggling with data sprawl and misalignment across their disparate teams and tools, with negative impact to the speed and success of their transformation efforts,” said Louise K. Allen, Chief Product Officer. “The platform innovations released today change how the enterprise leverages and connects data, transitioning it from an unusable repository to an invaluable asset. We are breaking down data silos by connecting strategic priorities and the teams delivering the work, enabling organization-wide visibility to keep outcomes front and center.”

Accelerate Outcomes with Comprehensive Data Visibility and Personalization

Introducing Planview.Me™, an easy-to-use, personalized platform experience designed to bring data, insights, and work together into a single view. With Planview.Me, teams and individuals across roles and personas can:

  • Create configurable, unique views based on status, progress, stakeholder needs, and other data-oriented use cases.
  • Reduce platform clicks to surface the right information at the right time with clear actions in a single view, for an improved user experience.
  • Take action, investigate, respond, and react with a single click, increasing efficiency by having relevant data available at your fingertips.
  • Bring data and insight transparency into all decisions and to all decision-makers within the organization.

Uplevel Your Productivity with Actionable AI-Insights and Expert Guidance

Planview® Copilot is now available across Strategic Portfolio Management, Enterprise Agile Planning (EAP), Value Stream Management (VSM), and Digital Product Development solutions, including the Planview® Portfolios, Planview® Viz, Planview® AdaptiveWork, and Planview® AgilePlace products.

First introduced as an Early Access release in September 2023, Planview Copilot users can:

  • Converse with and question their data using natural language to glean insights, derive recommendations based on best practices, and inform strategic decisions.
  • Instantly tap into decades of Planview knowledge, best practices, and key learnings​.
  • Surface hidden insights and delivery risks across multiple initiatives, value streams, products, and projects​.
  • Increase productivity by analyzing and synthesizing vast amounts of data in seconds.

Further boosting Planview’s AI-enabled platform capabilities, Planview is strengthening its early-warning systems with additional sentiment analysis and aggregation across key products, including Planview Portfolios, Planview® AgilePlace, and Planview® ProjectPlace. Sentiment analysis can:

  • Create sentiment scores based on emotional tone across multiple comments and text entries to provide an overview of product, project, or work health.
  • Analyze trends over time to understand whether large bodies of work reflect positive, neutral, or negative sentiments.
  • Accurately reflect the status of the work outside of traditional red, amber, and green indicators.

“Connecting value stream data is a critical first step in creating the visibility needed to understand where your organizational challenges lie,” says Mik Kersten, Chief Technology Officer. “With Planview Copilot’s new skills and our robust early warning systems now embedded across the entire Planview Platform, we are empowering organizations with more than visibility – we are giving them the actionable insights that will shape their strategic decisions, drive productivity, and accelerate time to value for digital transformations.”

Redefine How Work Gets Done with Less Disruption and More Enterprise-wide Work Connectivity

With enhanced connectivity between Planview Portfolios and Planview ProjectPlace, Planview is bringing traditionally ungoverned work into the purview of portfolio leadership to ensure alignment, oversight, and governance while empowering teams to deliver projects with easy-to-use capabilities like Gantt, kanban, and document storage, in discrete workspaces with no manual status reporting. This enhancement drives greater team autonomy, allowing teams to continue working within their projects and programs without disruption, while providing leadership with the right level of visibility and oversight.

Finally, Planview introduces the Planview® Universal Connector, a strong addition to the 60+ software tool connectors it already has available. The Universal Connector enables organizations to automate and seamlessly integrate their third-party or homegrown software development tools directly into the Planview® Platform. By unlocking data siloed in disparate software delivery tools, data and work can flow directly into the Planview Platform, increasing data visibility and keeping productivity high without disrupting the native work and workflow processes of the delivery teams.

Additional Resources:

  • Learn more about the Planview Platform
  • Check out the Platform Demo to learn more about Planview.Me and Planview Copilot
  • Learn more about Planview Copilot
  • Register to attend Planview Accelerate on May 14-15, 2024, to learn more about Planview’s approach to Strategic Portfolio Management, Digital Product Development, Data, Generative AI, and Connected Work

About Planview

Planview is the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Development (DPD), enabling organizations to plan and deliver large-scale digital transformation initiatives. Planview empowers organizations to improve time-to-market and predictability, increase efficiency to unlock capacity, and ensure their most strategic product and project initiatives deliver the desired business outcomes. Our connected platform of solutions underpins the business and digital transformations of more than 4,500 customers and 2.7 million users globally, including 59 of the Fortune 100. Headquartered in Austin, Texas, Planview has over 1,400 employees worldwide.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240429197434/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye